BioInvent Stumbles In Busy Multiple Myeloma Space
The US FDA has halted the biotech company’s Phase II trial in multiple myeloma, a space that has seen a number of new drugs recently enter the market.
You may also be interested in...
With its focus firmly on oncology, the Swedish biotech, and its outgoing chief, believe the company now needs someone with more scientific skills in the CEO role.
Busy stretch before Christmas holidays sees two deals around oncolytic virus therapeutics, a Middle East partnership for Orexigen’s Contrave, immuno-oncology deals involving Pfizer and ElsaLys, and Roche and ImmuNext partnering to develop drugs targeting the VISTA pathway.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.